Joaquim Bellmunt, MD, PhD, Genitourinary Cancer | Dana-Farber Cancer Institute Dana-Farber Cancer Institute 1:54 1 year ago 580 Скачать Далее
Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer OncLive 2:06 5 years ago 292 Скачать Далее
How can we improve responses to immunotherapy in patients with bladder cancer? VJOncology 1:21 2 years ago 205 Скачать Далее
Chemotherapy vs. Immunotherapy: side effects and more The Patients' Channel 1:50 7 years ago 696 Скачать Далее
Treatment options and their rollout for patients with metastatic urothelial carcinoma VJOncology 1:52 10 months ago 48 Скачать Далее
Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer OncLive 1:13 6 years ago 135 Скачать Далее
Breakthroughs in urothelial cancer treatment at ESMO 2023 VJOncology 3:38 10 months ago 351 Скачать Далее
JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer VJOncology 1:12 2 years ago 394 Скачать Далее
Perioperative treatment strategies for high-risk bladder cancer VJOncology 4:04 1 year ago 99 Скачать Далее
KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma VJOncology 1:09 7 years ago 203 Скачать Далее
Long term outcomes in JAVELIN Bladder 100: avelumab in urothelial carcinoma VJOncology 2:03 2 months ago 50 Скачать Далее
Dr. Bellmunt on Immunotherapy Combination Trials in Bladder Cancer OncLive 0:55 6 years ago 71 Скачать Далее
Overview of urothelial carcinoma treatment landscape – the promise of immunotherapy VJOncology 4:00 7 years ago 422 Скачать Далее
Sequencing and treatment strategies in advanced urothelial carcinoma VJOncology 1:26 2 months ago 32 Скачать Далее
